The role of biosimilars in enhancing global access to psoriasis treatment
Journal of Investigative Dermatology · 2026-04
DOI: 10.1016/j.jid.2026.01.047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Investigative Dermatology, 2026-04. Verfasst von Yasmina Behlock und 14 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Hopital Universitaire de Bruxelles (HUB) - Erasmus Hospital, Brussels, Belgium. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The introduction of biosimilars for the treatment of moderate-to-severe psoriasis has demonstrated efficacy and safety comparable to those of originator biologics, with the potential to improve cost-effectiveness. We explored the potential for biosimilars to improve access to biologics for psoriasis, especially in low- and middle-income countries, where costs often limit access to originators. The analysis was based on a systematic review conducted as part of the submission process to include adalimumab and ustekinumab in the World Health Organization Essential Medicines List for psoriasis. Among the 17 studies included in the systematic review, we focused on those that provided data evaluating the cost and/or cost-effectiveness of biosimilars versus originators in the treatment of psoriasis. Two studies met the inclusion criteria. The first was a cohort-based Markov model, which showed that biosimilar adalimumab was cost-effective compared with the originator adalimumab for moderate-to-severe psoriasis. The second, using a cost-per-responder model, found that the adalimumab biosimilar had the lowest cost-per PASI complete clearance (PASI100) responder among the anti-TNF therapies. Biosimilars have a key role in reducing costs and expanding treatment availability for patients with psoriasis. Further health economic studies focusing on psoriasis are required to demonstrate how biosimilars can improve access to biologics in this condition.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dermatology Department, Hopital Universitaire de Bruxelles (HUB) - Erasmus Hospital, Brussels, Belgium.
- Division of Population Health, Health Services Research and Primary Care, Manchester Centre for Health Economics, School of Health Sciences, The University of Manchester, Manchester, United Kingdom.
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.
- Department of Dermatology, Southern Philippines Medical Center, Davao City, Philippines.
- School of Medicine, Nankai University, Tianjin, China.
- Medical Science, Medicom Medical Publishers, Amsterdam, The Netherlands.
Zitieren
APA
Behlock, Y., Gavan, S. P., Graier, T., Guevara, B. E., He, J., Giles, R. H., Wright, A. K., Ashcroft, D. M., Lim, H. W., De La Cruz, C., French, L. E., Foley, P., Lwin, S., Griffiths, C. E. M., & Van de Kerkhof, P. C. M. (2026). The role of biosimilars in enhancing global access to psoriasis treatment. Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2026.01.047
Vancouver
Behlock Y, Gavan SP, Graier T, Guevara BE, He J, Giles RH, et al. The role of biosimilars in enhancing global access to psoriasis treatment. Journal of Investigative Dermatology. 2026. doi:10.1016/j.jid.2026.01.047
BibTeX
@article{Behlock2026,
author = {Behlock, Yasmina and Gavan, Sean P and Graier, Thomas and Guevara, Bryan Edgar and He, Juan and Giles, Rachel H and Wright, Alison K and Ashcroft, Darren M and Lim, Henry W and De La Cruz, Claudia and French, Lars E and Foley, Peter and Lwin, Su and Griffiths, Christopher E M and Van de Kerkhof, Peter C M},
title = {The role of biosimilars in enhancing global access to psoriasis treatment},
journal = {Journal of Investigative Dermatology},
year = {2026},
doi = {10.1016/j.jid.2026.01.047}
}
EUVIMED